Intangible Assets

HHS appears to rely on service execution and customer relationships more than on hard-to-replicate intellectual property, so its pricing power is weaker than peers with proprietary software, branded products, or regulated assets.

The provided metrics show negative ROIC and ROCE, which indicates that any intangible advantage is not yet translating into durable excess returns versus stronger healthcare-services peers.

In a staffing and workforce-solutions model, brand and reputation can support client trust, but those benefits are typically easier to replicate than the protected clinical or technology assets seen at higher-moat peers.

Compared with peers that own proprietary platforms or embedded clinical workflows, HHS likely has limited intangible asset depth because its offerings are more service-based and less protected by exclusive IP or regulation.

Switching Costs

HHS can create some switching friction through client-specific staffing processes, compliance requirements, and operational familiarity, but these frictions are usually lower than the embedded workflow lock-in seen at software-heavy peers.

The negative TTM ROIC suggests that any retention benefit from switching costs is not strong enough to produce durable economic profits versus peers with deeper integration.

Healthcare staffing relationships can be sticky when service quality is high, yet buyers can still rebid or multi-source, which limits long-term pricing power relative to more embedded competitors.

Compared with peers that control mission-critical systems or exclusive provider networks, HHS likely has only moderate switching costs because customers can replace service vendors without fully disrupting core operations.

Network Effects

HHS does not appear to operate a platform where more users materially improve the product for other users, so network effects are limited versus marketplace or software peers.

The business model is primarily bilateral service delivery, which means customer value is not self-reinforcing in the way that peer networks or data ecosystems can be.

Any referral or reputation benefits are indirect and do not create the compounding adoption loop that would support durable moat expansion.

Compared with peers that benefit from two-sided marketplaces or data-driven ecosystems, HHS has little evidence of network-based advantage.

Cost Advantage

The negative ROIC and ROCE imply that HHS is not currently converting scale into a clear cost advantage versus peers.

Healthcare staffing is labor-intensive, so wage pressure and local competition usually prevent sustained unit-cost leadership unless a firm has exceptional scale or automation.

Asset turnover is solid, but that efficiency alone does not prove a structural cost edge because peers can often match utilization through similar operating models.

Compared with larger or more automated peers, HHS likely lacks a durable cost advantage because labor is the main input and is broadly available to competitors.

Efficient Scale

HHS may benefit from some local or niche efficient-scale characteristics where a limited number of providers can serve a market efficiently, but the industry is not naturally monopolistic.

The service model can support regional density, yet that advantage is usually weaker than the scale economics of national platforms or regulated utilities.

Negative returns suggest that any scale benefit is not currently strong enough to prevent competitive pricing pressure or to generate excess returns versus peers.

Compared with peers in highly concentrated markets, HHS likely has only modest efficient-scale protection because customers can still source staffing from multiple vendors.

Overall Score

HHS shows limited moat durability versus peers because its business appears service-based, labor-intensive, and only modestly sticky, while the provided profitability metrics show negative excess returns that argue against a strong structural advantage. The strongest relative support comes from some switching friction and possible local density, but these are not deep enough to offset weak evidence for intangible assets, network effects, or cost leadership.